NRx Pharmaceuticals, Inc. (NRXP)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Jonathan C. Javitt M.D., M.P.H.
|
Co-Founder, Chairman & CEO | 846.77k | -- | 1957 |
|
Mr. Michael S. Abrams M.B.A.
|
CFO & Treasurer | 363.08k | -- | 1970 |
|
Mr. Joseph M. Casper
|
Chief Operating Officer | -- | -- | 1951 |
|
Dr. Riccardo Panicucci Ph.D.
|
Chief Manufacturing & Technology Officer | 240k | -- | 1962 |
|
Dr. Hervé Perron HDR, Ph.D.
|
Chief Scientist | -- | -- | 1959 |
|
Suzanne Messere
|
Investor Relations | -- | -- | -- |
|
Mr. Michael Taylor
|
Chief Development Officer & Director | -- | -- | 1975 |
|
Dr. Philip T. Lavin Ph.D.
|
Chief Methodologist | -- | -- | 1947 |
|
Dr. Dennis K. McBride Ph.D.
|
Chief Strategy Officer & Director | 38.46k | -- | 1955 |
|
Prof. Joshua C. Brown M.D., Ph.D.
|
Chief Medical Innovation Officer | -- | -- | -- |
NRx Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 29
Description
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
Corporate Governance
Upcoming Events
November 12, 2026 at 9:00 PM UTC
NRx Pharmaceuticals, Inc. Earnings Date
